Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteomics01:33

Proteomics

10.0K
A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...
10.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

61
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
61

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026
Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026
Same author

Characteristics, treatment and survival of older patients with metastatic triple negative breast cancer from the ESME mBC real-world national cohort: a comparison with younger women.

Breast (Edinburgh, Scotland)·2026
Same author

CRL2<sup>FEM1B</sup> uses heme to recruit BACH1 for degradation and regulate ferroptosis in lung cancer.

Molecular cell·2026
Same author

Prickle and Ror modulate Dishevelled-Vangl interaction to regulate non-canonical Wnt signaling during convergent extension in <i>Xenopus</i>.

eLife·2026
Same author

The ribosome-associated N-terminal acetyltransferase B coordinates global proteostasis and autophagy in plants by creating Ac/N-degrons.

Nature communications·2026

Related Experiment Video

Updated: Mar 12, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K

How may targeted proteomics complement genomic data in breast cancer?

Mathilde Guerin1,2, Anthony Gonçalves1,2, Yves Toiron2

  • 1a Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille Protéomique , Marseille , France.

Expert Review of Proteomics
|November 5, 2016
PubMed
Summary

Novel proteomics technologies offer a more precise understanding of breast cancer (BC) by analyzing proteins, which are key drug targets. These advanced methods complement genomic data for personalized BC treatment.

Keywords:
Proteomicsbreast cancermass spectrometryselected reaction monitoringtargeted

More Related Videos

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.8K
Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
10:59

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments

Published on: February 7, 2025

1.9K

Related Experiment Videos

Last Updated: Mar 12, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K
Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification
10:37

Deep Proteome Profiling by Isobaric Labeling, Extensive Liquid Chromatography, Mass Spectrometry, and Software-assisted Quantification

Published on: November 15, 2017

12.8K
Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments
10:59

Glycomics-Guided Glycoproteomics Facilitates Comprehensive Profiling of the Glycoproteome in Complex Tumor Microenvironments

Published on: February 7, 2025

1.9K

Area of Science:

  • Oncology
  • Proteomics
  • Biomarker Discovery

Background:

  • Breast cancer (BC) is the most prevalent female cancer globally, with molecular subtypes identified.
  • Genomic and transcriptomic data often show discrepancies with protein expression due to post-translational modifications.
  • Proteins are crucial for cellular functions and represent primary targets for anticancer drugs.

Purpose of the Study:

  • To review novel proteomics technologies for breast cancer biomarker validation.
  • To highlight the potential of these technologies in complementing genomic data for precise tumor characterization.

Main Methods:

  • Discussion of Reverse Phase Protein Array (RPPA) and mass-spectrometry (MS) based proteomics.
  • Comparison with traditional methods like immunohistochemistry and ELISA.
  • Focus on targeted proteomic approaches.

Main Results:

  • Proteomics offers a more accurate reflection of cellular functions compared to genomics alone.
  • Novel MS and RPPA technologies provide enhanced capabilities for protein analysis.
  • These methods can validate proteins as diagnostic, prognostic, and predictive biomarkers.

Conclusions:

  • Targeted proteomic approaches are essential for precise breast cancer characterization.
  • Complementing genomic data with proteomics enables more personalized treatment strategies.
  • Advanced proteomics can facilitate the routine monitoring of biomarkers in clinical practice.